In breast cancer, where human epidermal growth factor receptor 2 (HER2) gene amplication is detected in 25% of patients [4], a monoclonal antibody targeting HER2, trastuzumab, (Herceptin) significantly improves the survival of these patients [5]. Here, ERBB2 is linked to breast cancer.